🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Thyroid Associated Ophthalmopathies

A Study of GenSci098 in Subjects With Active Thyroid Eye Disease NCT06569758Phase 11 site📍 Shanghai Changchun GeneScience Pharmaceutical Co., Ltd. · Tests: GenSci098, GenSci098 Placebo Screening, Classification, and Outcome Prediction Ensemble Using Orbital MRI for Thyroid Eye Disease: The TED SCOPE National Multicenter Registry Study NCT07716397n/a1 site📍 Shanghai Shanghai Changzheng Hospital · Tests: MRI scan，ocular ultrasound A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease NCT07265258Phase 41 site📍 Shanghai Innovent Biologics (Suzhou) Co. Ltd. · Tests: Teprotumumab N01, Methylprednisolone Hydroxychloroquine in Mild Graves' Orbitopathy NCT05126147Phase 42 sites📍 Hsinchu📍 Taipei National Taiwan University Hospital · Tests: Hydroxychloroquine A Clinical Study of Cizutamig in Thyroid Eye Disease NCT07597200Phase 114 sites📍 Hefei📍 Beijing📍 Fuzhou Candid Therapeutics · Tests: Cizutamig will be dosed according to the protocol. The Safety and Efficacy of Sequential Hormone Therapy and IBI311 Therapy in Patients With Active Moderate to Severe TAO in the Initial Treatment. NCT07152340Phase 42 sites📍 Changhua📍 Shanghai Shanghai Changzheng Hospital · Tests: IBI311, Glucocorticoids Treatment of Chronic Thyroid Eye Disease With MHB018A NCT07622121Phase 31 site📍 Coral Gables Minghui Pharmaceutical (Hangzhou) Ltd · Tests: MHB018A injection, MHB018A injection Placebo Tofacitinib for Glucocorticoid-Resistant Moderate-to-Severe Thyroid Eye Disease NCT07547930Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Tofacitinib Systemic Inflammation, Thyroid Autoimmunity and Neuroretinal Changes in Graves Disease NCT07480720n/a1 site📍 Elâzığ Elazıg Fethi Sekin Sehir Hastanesi Bimatoprost as a Treatment for Graves' Orbitopathy NCT03708627EARLY Phase 11 site📍 Seattle Johns Hopkins University · Tests: Bimatoprost Ophthalmic Establishment of Multiparametric Prediction Models for Moderate to SevereThyroid Associated Ophthalmopathy NCT06590220n/a1 site📍 Shanghai Shanghai Changzheng Hospital A Study of IBI3031 in Participants With Thyroid Eye Disease NCT07622368Phase 11 site📍 Shenyang Innovent Biologics (Suzhou) Co. Ltd. · Tests: IBI3031, placebo Orbital Radiotherapy in Grave's Ophthalmopathy 1 Week vs 2 Weeks (OraGO-1 Trial) NCT06392906Phase 31 site📍 Bangkok Noi Janjira Petsuksiri · Tests: Short course radiation therapy, Standard course radiation therapy Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease NCT07400757NA1 site📍 Taipei Taipei Veterans General Hospital, Taiwan · Tests: Atorvastatin (Lipitor), Vitamin D Eye Tracking Study on Eye Movement Function and Visual Attention Patterns in Patients With Thyroid-Associated Ophthalmopathy NCT07381413n/a1 site📍 Shanghai Shanghai Changzheng Hospital · Tests: Non-invasive Eye Tracking Assessment Efficacy and Safety of Sequential Hormone Therapy and Tetuzumab Therapy in Patients With Moderate to Severe TAO in the Active Stage After Glucocorticoid Treatment. NCT07152366Phase 41 site📍 Shanghai Shanghai Changzheng Hospital · Tests: IBI311, Glucocorticoids An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease NCT07438405Phase 28 sites📍 Little Rock📍 Kissimmee📍 Orland Park Amgen · Tests: AMG 732 The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction NCT06275373n/a1 site📍 Bethesda Walter Reed National Military Medical Center · Tests: Teprotumumab Injection [Tepezza] Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease NCT04936854Phase 21 site📍 Bergen Haukeland University Hospital · Tests: Sirolimus 1 mg Oral Tablet, Methylprednisolone Comparative Evaluation of 68Ga-FAPI and 68Ga-DOTATATE PET/CT and PET/MRI in Thyroid Eye Disease NCT07835607n/a1 site📍 Chongqing Daping Hospital and the Research Institute of Surgery of th… · Tests: 68Ga-FAPI PET/CT and PET/MR Imaging, 68Ga-DOTATATE PET/CT and PET/MR Imaging Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting NCT05012033n/a1 site📍 London Imperial College London · Tests: No intervention - prednisolone is taken as part if routine clinical care. Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO NCT07152392Phase 41 site📍 Shanghai Shanghai Changzheng Hospital · Tests: IBI311, Follew-up Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease NCT06359795NA1 site📍 Beijing Peking University Third Hospital · Tests: 18F-AlF-FAPI PET/CT, 99mTc-DTPA SPECT/CT Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease NCT07262476Phase 31 site📍 Shanghai Minghui Pharmaceutical (Hangzhou) Ltd · Tests: MHB018A injection Construction and Application of Precise Diagnosis and Treatment System for Thyroid-associated Ophthalmopathy NCT07124572n/a1 site📍 Hangzhou Second Affiliated Hospital, Zhejiang University, School of … · Tests: Imaging and ocular examinations Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED) NCT07753603Phase 318 sites📍 Glendale📍 Beverly Hills📍 Canoga Park Sling Therapeutics, Inc. · Tests: linsitinib, Placebo Describe the Progression of Inflammatory Orbitopathy and the Biological Progression of Patients Receiving Second-line Treatment NCT07117981n/a9 sites📍 Paris📍 Caen📍 Lyon Centre Hospitalier National d'Ophtalmologie des Quinze-Ving… Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease. NCT07423013NA1 site📍 Beijing Peking University Third Hospital · Tests: [18F]AlF-NOTA-FAPI-04PET/CT, 5.0-T high-resolution MRI Treatment of Graves´ophthalmopathy with Simvastatin (GO-S) NCT03131726Phase 31 site📍 Malmö Lund University · Tests: Simvastatin 40mg A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy NCT06927375Phase 41 site📍 Shanghai Shanghai Ninth People's Hospital Affiliated to Shanghai Jia… · Tests: Tocilizumab(400mg) combined with Flupentixol Melitracen(0.5mg:10mg), Tocilizumab(400mg)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy